HRP20180267T1 - Rekombinantni hcmv i rhcmv vektori i njihovo korištenje - Google Patents
Rekombinantni hcmv i rhcmv vektori i njihovo korištenje Download PDFInfo
- Publication number
- HRP20180267T1 HRP20180267T1 HRP20180267TT HRP20180267T HRP20180267T1 HR P20180267 T1 HRP20180267 T1 HR P20180267T1 HR P20180267T T HRP20180267T T HR P20180267TT HR P20180267 T HRP20180267 T HR P20180267T HR P20180267 T1 HRP20180267 T1 HR P20180267T1
- Authority
- HR
- Croatia
- Prior art keywords
- rhcmv
- hcmv
- recombinant
- vector according
- vector
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims 19
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims 5
- 238000012217 deletion Methods 0.000 claims 5
- 230000037430 deletion Effects 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 208000035473 Communicable disease Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108700039887 Essential Genes Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 101150003185 US12 gene Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 108010051219 Cre recombinase Proteins 0.000 claims 1
- 101100048387 Human cytomegalovirus (strain AD169) UL64 gene Proteins 0.000 claims 1
- 101100195396 Human cytomegalovirus (strain Merlin) RL11 gene Proteins 0.000 claims 1
- 108091078291 RL11 family Proteins 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 101150087840 UL11 gene Proteins 0.000 claims 1
- 101150072074 UL28 gene Proteins 0.000 claims 1
- 101150081727 UL32 gene Proteins 0.000 claims 1
- 101150104684 UL44 gene Proteins 0.000 claims 1
- 101150033660 UL6 gene Proteins 0.000 claims 1
- 101150095805 UL7 gene Proteins 0.000 claims 1
- 101150088910 UL82 gene Proteins 0.000 claims 1
- 101150022492 UL83 gene Proteins 0.000 claims 1
- 101150026859 UL9 gene Proteins 0.000 claims 1
- 101150117356 UL94 gene Proteins 0.000 claims 1
- 101150074007 UL99 gene Proteins 0.000 claims 1
- 101150065606 US13 gene Proteins 0.000 claims 1
- 101150004205 US14 gene Proteins 0.000 claims 1
- 101150071882 US17 gene Proteins 0.000 claims 1
- 101150044878 US18 gene Proteins 0.000 claims 1
- 101150110932 US19 gene Proteins 0.000 claims 1
- 101150049278 US20 gene Proteins 0.000 claims 1
- 101150114976 US21 gene Proteins 0.000 claims 1
- 101150044134 US28 gene Proteins 0.000 claims 1
- 101150016895 US29 gene Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 101150002378 gC gene Proteins 0.000 claims 1
- 101150015940 gL gene Proteins 0.000 claims 1
- 244000052637 human pathogen Species 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- -1 pp65 family Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 101150046896 trm1 gene Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/869—Herpesviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
- C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
- C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (12)
1. Rekombinantni RhCMV ili HCMV vektor koji sadrži sekvencu nukleinske kiseline koja kodira heterologni antigen, pri čemu heterologni antigen je ljudski patogen specifičan antigen izoliran iz virusa ljudske imunodeficijencije (HIV),
naznačen time da vektor uključuje brisanje jednog ili više gena RhCMV ili HCMV gena koji su esencijalni za ili povećavaju replikaciju.
2. Rekombinantni RhCMV ili HCMV vektor prema zahtjevu 1, naznačen time da je barem jedan esencijalni gen ili povećavajući gen odabran između UL82, UL94, UL32, UL99, UL115 ili UL44, ili njihovog homologa.
3. Rekombinantni RhCMV ili HCMV vektor prema bilo kojem od zahtjeva 1-2, naznačen time da sadrži brisanje US2, US3, US6 ili US11 ili njihovog homologa, te naročito sadrži brisanje Rh158-166 ili njegovog homologa.
4. Rekombinantni HCMV vektor prema bilo kojem od zahtjeva 1-3 naznačen time da sadrži brisanje UL64 ili US29, ili njihove kombinacije.
5. Rekombinantni RhCMV vektor ili HCMV vektor prema bilo kojem od zahtjeva 1-4, naznačen time da RhCMV vektor ili HCMV vektor ima brisanje u područjima gena koja nisu neophodna za rast in vivo, naročito gdje su područja gena su odabrana iz skupine koju čine RL11 obitelj, pp65 obitelj, US12 obitelj i US28 obitelj.
6. Rekombinantni RhCMV vektor prema zahtjevu 5, naznačen time da su RhCMV genska područja odabrana iz skupine koja sadrži Rh13-Rh29, Rh111-Rh112, Rh191-Rh202 i Rh214-Rh220, naročito gdje su područja RhCMV gena odabrana iz skupine koju čine Rh13.1, Rh19, Rh20, Rh23, Rh24, Rh112, Rh190, Rh192, Rh196, Rh198, Rh199, Rh200, Rh201, Rh202 i Rh220.
7. Rekombinantni HCMV vektor prema zahtjevu 5, naznačen time da su područja HCMV gena odabrana iz skupine koju čine RL11, UL6, UL7, UL9, UL11, UL83 (pp65), US12, US13, US14, US17, US18, US19 , US20, US21 i UL28.
8. Rekombinantni RhCMV ili HCMV vektor prema bilo kojem od zahtjeva 1-7, naznačen time da vektor sadrži LoxP mjesta koja okružuju esencijalni gen ili područje RhCMV ili HCMV genoma.
9. Rekombinantni RhCMV ili HCMV vektor prema bilo kojem od zahtjeva 1-7, naznačen time da vektor sadrži sekvencu nukleinske kiseline koja kodira tetraciklin (Tet)-reguliranu Cre rekombinazu.
10. Pripravak naznačen time da sadrži rekombinantni RhCMV ili HCMV vektor prema bilo kojem od zahtjeva 1-9 i farmaceutski prihvatljiv nosač.
11. Rekombinantni RhCMV ili HCMV vektor prema bilo kojem od zahtjeva 1-9, ili pripravak prema zahtjevu 10, naznačen time da je za uporabu u postupku liječenja subjekta sa zaraznom bolesti, pri čemu je zarazna bolest uzrokovana virusom humane imunodeficijencije (HIV).
12. Rekombinantni RhCMV ili HCMV vektor prema bilo kojem od zahtjeva 1-9, ili pripravak prema zahtjevu 10, naznačen time da je za uporabu u postupku liječenja subjekta koji je izložen riziku zaraze sa zaraznom bolesti, pri čemu je zarazna bolest uzrokovana virusom humane imunodeficijencije HIV.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33497610P | 2010-05-14 | 2010-05-14 | |
US37691110P | 2010-08-25 | 2010-08-25 | |
PCT/US2011/029930 WO2011119920A2 (en) | 2010-03-25 | 2011-03-25 | Cmv glycoproteins and recombinant vectors |
PCT/US2011/036657 WO2011143653A2 (en) | 2010-05-14 | 2011-05-16 | Recombinant hcmv and rhcmv vectors and uses thereof |
EP11781407.9A EP2569436B8 (en) | 2010-05-14 | 2011-05-16 | Recombinant hcmv and rhcmv vectors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20180267T1 true HRP20180267T1 (hr) | 2018-04-20 |
Family
ID=44915020
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180267TT HRP20180267T1 (hr) | 2010-05-14 | 2018-02-13 | Rekombinantni hcmv i rhcmv vektori i njihovo korištenje |
HRP20180601TT HRP20180601T1 (hr) | 2010-05-14 | 2018-04-16 | Rekombinantni vektori hcmv i rhcmv i njihova upotreba |
HRP20200698TT HRP20200698T1 (hr) | 2010-05-14 | 2020-04-30 | Rekombinantni hcmv i rhcmv vektori koji kodiraju heterologni antigen izoliran iz hepatitis b virusa i njihove uporabe |
HRP20201406TT HRP20201406T1 (hr) | 2010-05-14 | 2020-09-03 | Rekombinantni hcmv i rhcmv vektori koji kodiraju heterologni antigen izoliran iz virusa paramyxoviridae i njihove uporabe |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180601TT HRP20180601T1 (hr) | 2010-05-14 | 2018-04-16 | Rekombinantni vektori hcmv i rhcmv i njihova upotreba |
HRP20200698TT HRP20200698T1 (hr) | 2010-05-14 | 2020-04-30 | Rekombinantni hcmv i rhcmv vektori koji kodiraju heterologni antigen izoliran iz hepatitis b virusa i njihove uporabe |
HRP20201406TT HRP20201406T1 (hr) | 2010-05-14 | 2020-09-03 | Rekombinantni hcmv i rhcmv vektori koji kodiraju heterologni antigen izoliran iz virusa paramyxoviridae i njihove uporabe |
Country Status (18)
Country | Link |
---|---|
US (3) | US9249427B2 (hr) |
EP (5) | EP3739054A1 (hr) |
AU (5) | AU2011252792C1 (hr) |
CA (2) | CA3040225A1 (hr) |
CY (4) | CY1119944T1 (hr) |
DK (3) | DK2569436T3 (hr) |
ES (4) | ES2819623T3 (hr) |
HK (2) | HK1256651A1 (hr) |
HR (4) | HRP20180267T1 (hr) |
HU (4) | HUE036122T2 (hr) |
LT (4) | LT3351636T (hr) |
NO (2) | NO2772265T3 (hr) |
PL (4) | PL2772265T3 (hr) |
PT (3) | PT2772265T (hr) |
RS (2) | RS57274B1 (hr) |
SI (4) | SI3351636T1 (hr) |
TR (1) | TR201802741T4 (hr) |
WO (2) | WO2011143650A2 (hr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102844663B (zh) * | 2010-01-27 | 2016-01-06 | 俄勒冈健康科学大学 | 基于巨细胞病毒的免疫原性制剂 |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
HUE036122T2 (hu) | 2010-05-14 | 2018-06-28 | Univ Oregon Health & Science | Rekombináns HCMV és RhCMV vektorok és alkalmazásaik |
US9701943B2 (en) * | 2011-04-15 | 2017-07-11 | Cecilia Nauclér | Genetic variant of cytomegalovirus (CMV) |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CA2890061A1 (en) * | 2012-12-04 | 2014-06-12 | Merck Sharp & Dohme Corp. | Conditional replicating viral vectors |
AU2014207618A1 (en) | 2013-01-16 | 2015-08-06 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
GB201301119D0 (en) * | 2013-01-22 | 2013-03-06 | Vaxxit Srl | Viral vaccines |
ES2696703T3 (es) * | 2013-03-05 | 2019-01-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que permiten el control del direccionamiento de los linfocitos T |
US20140335115A1 (en) * | 2013-05-07 | 2014-11-13 | Oregon Health & Science University | Suppressors of mature t cells |
EP3063274A4 (en) * | 2013-10-29 | 2017-04-05 | The University Of Sydney | Cmv immuno-stimulatory composition |
SG11201607287XA (en) * | 2014-03-01 | 2016-09-29 | Univ Texas | Recombinant isfahan viral vectors |
MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
CN107002048B (zh) | 2014-07-16 | 2021-07-06 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
MA40783A (fr) * | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
GB201501523D0 (en) * | 2015-01-30 | 2015-03-18 | Univ Plymouth | Differential immune response modulation |
AU2016219317A1 (en) * | 2015-02-10 | 2017-08-31 | Oregon Health & Science University | Methods and compositions useful in generating non canonical CD8+ T cell responses |
US20160346362A1 (en) * | 2015-05-29 | 2016-12-01 | Agenovir Corporation | Methods and compositions for treating cytomegalovirus infections |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
GB201514034D0 (en) | 2015-08-08 | 2015-09-23 | Univ Plymouth | Improvements in or relating to DNA recombination |
JP7133468B2 (ja) * | 2015-11-20 | 2022-09-08 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ | マイクロrna認識エレメントを含むcmvベクター |
WO2017112797A1 (en) | 2015-12-22 | 2017-06-29 | Thomas Jefferson University | Intra-lesional cmv-based cancer vaccines |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
WO2017223146A1 (en) * | 2016-06-22 | 2017-12-28 | Aeras | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
EP3475446A1 (en) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
EP3529363A4 (en) * | 2016-10-18 | 2020-05-06 | Oregon Health & Science University | CYTOMEGALOVIRUS VECTORS, CALLING OUT T-CELLS, RESTRICTED BY A LARGE HISTOCOMPATIBILITY COMPLEX E-MOLECULE |
EP3697806A4 (en) | 2017-10-17 | 2021-10-27 | International AIDS Vaccine Initiative, Inc. | TUBERCULOSIS ANTIGEN CASSETTES |
EP3762025A4 (en) * | 2018-03-09 | 2021-12-01 | The Regents of the University of California | VECTORS OF CMV AND ASSOCIATED USES |
US20210047626A1 (en) | 2018-04-24 | 2021-02-18 | Merck Sharp & Dohme Corp. | Scalable chromatography process for purification of human cytomegalovirus |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
EP3905880A4 (en) | 2019-01-03 | 2022-10-05 | Merck Sharp & Dohme Corp. | SUPPLEMENTED SERUM CONTAINING CULTURE MEDIUM FOR ENHANCEMENT OF ARPE-19 GROWTH AND FOR THE PREPARATION OF A HUMAN CYTOMEGALOVIRUS VACCINE |
WO2020188111A1 (en) | 2019-03-21 | 2020-09-24 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
US10632186B1 (en) | 2019-03-21 | 2020-04-28 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
EP3980071A4 (en) * | 2019-06-07 | 2023-10-11 | Oregon Health & Science University | TUMOR-ASSOCIATED ANTIGEN-SPECIFIC T-CELL REACTIONS |
TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
TW202328167A (zh) | 2021-08-31 | 2023-07-16 | 美商維爾生物科技股份有限公司 | 結核病疫苗 |
TW202319070A (zh) * | 2021-08-31 | 2023-05-16 | 美商維爾生物科技股份有限公司 | 用於製造cmv載體的方法 |
AU2022339765A1 (en) | 2021-08-31 | 2024-01-25 | Vir Biotechnology, Inc. | Recombinant hcmv vectors and uses thereof |
WO2023059112A1 (ko) * | 2021-10-06 | 2023-04-13 | 주식회사 지앤피바이오사이언스 | 최적의 재조합 발현 구축물의 개발 |
WO2023133400A2 (en) * | 2022-01-07 | 2023-07-13 | Mayo Foundation For Medical Education And Research | Cytomegalovirus vectors and methods of use |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267965B1 (en) * | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
CA1327171C (en) | 1987-06-26 | 1994-02-22 | Lisa J. Hock | Recombinant human cytomegalovirus containing foreign gene and use thereof |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
SG49046A1 (en) | 1991-07-05 | 1998-05-18 | American Cyanamid Co | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus |
WO1995003399A2 (en) * | 1993-07-19 | 1995-02-02 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
EP0758396B1 (en) | 1994-04-29 | 2006-07-26 | Pharmacia & Upjohn Company LLC | Feline immunodeficiency virus vaccine |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
DE69535905D1 (de) | 1994-07-15 | 2009-02-26 | Coley Pharm Group Inc | Immunomodulatorische Oligonukleotide |
US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
EP0811057B1 (en) * | 1995-02-21 | 2006-04-26 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
AU712415B2 (en) | 1995-04-04 | 1999-11-04 | Cell Genesys, Inc. | Transplantation of genetically modified cells having low levels of class I MHC proteins on the cell surface |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
US6033671A (en) | 1996-07-31 | 2000-03-07 | Ortho Mcneil Pharmaceutical, Inc. | Identification of human cytomegalovirus genes involved in down-regulation of MHC class I heavy chain expression |
CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
DE19733364A1 (de) * | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
AU3910097A (en) * | 1997-08-05 | 1999-03-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Live recombinant vaccine comprising inefficiently or non-replicating vir us |
EP1067956B1 (en) | 1998-04-03 | 2007-03-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
US20020102536A1 (en) * | 1999-11-19 | 2002-08-01 | Xenova Research Limited | Preparation of human or animal herpesviruses |
US7204990B1 (en) * | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
EP1364037A4 (en) | 2001-02-02 | 2005-08-03 | Chemocentryx Inc | METHODS AND COMPOSITIONS USEFUL IN STIMULATING AN IMMUNE RESPONSE |
ATE488583T1 (de) | 2001-02-21 | 2010-12-15 | Wistar Inst | Rekombinant vektor, der ein infektiöses humanes cytomegalovirus genom mit konserviertem wildtyp- charakteristika klinisher isolate enthält |
GB0122232D0 (en) * | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
US20070015721A1 (en) * | 2001-09-20 | 2007-01-18 | Andrew Beaton | Hiv-gag codon-optimised dna vaccines |
CA2852277C (en) * | 2001-11-21 | 2018-02-20 | Guangping Gao | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
WO2003093455A2 (en) * | 2002-04-30 | 2003-11-13 | Avior Therapeutics, Inc. | Adenovirus vectors for immunotherapy |
CA2484669A1 (en) * | 2002-05-08 | 2003-11-20 | Akzo Nobel N.V. | Brachyspira hyodysenteriae vaccine |
DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
WO2005012545A2 (en) * | 2003-07-25 | 2005-02-10 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors |
CA2567597C (en) | 2004-05-25 | 2014-03-18 | Oregon Health And Science University | Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors |
EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
EP1799255A4 (en) * | 2004-06-25 | 2008-10-01 | Medimmune Vaccines Inc | RECOMBINANT HUMANESE CYTOMEGALOVIRUS AND HETEROLOGIST ANTIGENS CONTAINING VACCINES |
US8668564B2 (en) | 2005-01-24 | 2014-03-11 | Solution Champion Limited | Jackpot method and system |
EP1888622A1 (en) * | 2005-05-23 | 2008-02-20 | Oxxon Therapeutics Ltd. | Compositions for inducing an immune response against hepatitis b |
JP2009505680A (ja) * | 2005-08-31 | 2009-02-12 | ジェンベク、インコーポレイティッド | アデノウイルスベクターに基づくマラリアワクチン |
CA2626266C (en) | 2005-10-17 | 2015-09-08 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
WO2008112146A2 (en) | 2007-03-07 | 2008-09-18 | The Trustees Of The University Of Pennsylvania | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
WO2009023386A2 (en) | 2007-07-06 | 2009-02-19 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
PE20091434A1 (es) | 2007-10-30 | 2009-10-17 | Genentech Inc | Purificacion de anticuerpos por cromatografia de intercambio cationico |
WO2010101663A2 (en) | 2009-03-06 | 2010-09-10 | Mount Sinai School Of Medicine Of New York University | Live attenuated influenza virus vaccines comprising microrna response elements |
SG10201610827RA (en) | 2009-04-30 | 2017-02-27 | Ospedale San Raffaele Srl | Gene Vector |
BR112012015523A2 (pt) | 2009-12-23 | 2017-04-18 | 4-Antibody Ag | membros de ligação do citomegalovirus humano, composição contendo os mesmos, método de tratamento, moléculas de anticorpo, método de produção, molecular de ácido nucléico, célula hospedeira, e, método de neutralização do hcmv. |
CN102844663B (zh) | 2010-01-27 | 2016-01-06 | 俄勒冈健康科学大学 | 基于巨细胞病毒的免疫原性制剂 |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
CA2798214C (en) | 2010-05-05 | 2021-10-19 | Christian Thirion | Vaccine against beta-herpesvirus infection and use thereof |
HUE036122T2 (hu) * | 2010-05-14 | 2018-06-28 | Univ Oregon Health & Science | Rekombináns HCMV és RhCMV vektorok és alkalmazásaik |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
US20140227708A1 (en) | 2011-09-16 | 2014-08-14 | Oregon Health & Science University | Methods and kits used in identifying microrna targets |
US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
ES2696703T3 (es) | 2013-03-05 | 2019-01-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que permiten el control del direccionamiento de los linfocitos T |
CN107002048B (zh) | 2014-07-16 | 2021-07-06 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
AU2016219317A1 (en) | 2015-02-10 | 2017-08-31 | Oregon Health & Science University | Methods and compositions useful in generating non canonical CD8+ T cell responses |
JP7133468B2 (ja) | 2015-11-20 | 2022-09-08 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ | マイクロrna認識エレメントを含むcmvベクター |
WO2017223146A1 (en) | 2016-06-22 | 2017-12-28 | Aeras | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
EP3475446A1 (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
EP3529363A4 (en) | 2016-10-18 | 2020-05-06 | Oregon Health & Science University | CYTOMEGALOVIRUS VECTORS, CALLING OUT T-CELLS, RESTRICTED BY A LARGE HISTOCOMPATIBILITY COMPLEX E-MOLECULE |
-
2011
- 2011-05-16 HU HUE11781407A patent/HUE036122T2/hu unknown
- 2011-05-16 TR TR2018/02741T patent/TR201802741T4/tr unknown
- 2011-05-16 SI SI201131912T patent/SI3351636T1/sl unknown
- 2011-05-16 NO NO14162929A patent/NO2772265T3/no unknown
- 2011-05-16 DK DK11781407.9T patent/DK2569436T3/en active
- 2011-05-16 DK DK14162929.5T patent/DK2772265T3/en active
- 2011-05-16 NO NO11781407A patent/NO2569436T3/no unknown
- 2011-05-16 EP EP20155440.9A patent/EP3739054A1/en active Pending
- 2011-05-16 WO PCT/US2011/036628 patent/WO2011143650A2/en active Application Filing
- 2011-05-16 ES ES17205199T patent/ES2819623T3/es active Active
- 2011-05-16 CA CA3040225A patent/CA3040225A1/en active Pending
- 2011-05-16 PT PT141629295T patent/PT2772265T/pt unknown
- 2011-05-16 PL PL14162929T patent/PL2772265T3/pl unknown
- 2011-05-16 RS RS20180444A patent/RS57274B1/sr unknown
- 2011-05-16 ES ES11781407.9T patent/ES2660615T3/es active Active
- 2011-05-16 SI SI201131428T patent/SI2569436T1/en unknown
- 2011-05-16 LT LTEP17205199.7T patent/LT3351636T/lt unknown
- 2011-05-16 PT PT172051997T patent/PT3351636T/pt unknown
- 2011-05-16 SI SI201131464T patent/SI2772265T1/en unknown
- 2011-05-16 LT LTEP11781407.9T patent/LT2569436T/lt unknown
- 2011-05-16 EP EP17197412.4A patent/EP3333265B1/en active Active
- 2011-05-16 RS RS20180219A patent/RS56958B1/sr unknown
- 2011-05-16 HU HUE17197412A patent/HUE049725T2/hu unknown
- 2011-05-16 PT PT117814079T patent/PT2569436T/pt unknown
- 2011-05-16 EP EP17205199.7A patent/EP3351636B1/en active Active
- 2011-05-16 EP EP11781407.9A patent/EP2569436B8/en active Active
- 2011-05-16 LT LTEP17197412.4T patent/LT3333265T/lt unknown
- 2011-05-16 PL PL11781407T patent/PL2569436T3/pl unknown
- 2011-05-16 HU HUE14162929A patent/HUE037227T2/hu unknown
- 2011-05-16 HU HUE17205199A patent/HUE050909T2/hu unknown
- 2011-05-16 CA CA2798136A patent/CA2798136C/en active Active
- 2011-05-16 SI SI201131872T patent/SI3333265T1/sl unknown
- 2011-05-16 EP EP14162929.5A patent/EP2772265B1/en active Active
- 2011-05-16 ES ES14162929.5T patent/ES2666043T3/es active Active
- 2011-05-16 ES ES17197412T patent/ES2788198T3/es active Active
- 2011-05-16 PL PL17205199T patent/PL3351636T3/pl unknown
- 2011-05-16 DK DK17197412.4T patent/DK3333265T3/da active
- 2011-05-16 PL PL17197412T patent/PL3333265T3/pl unknown
- 2011-05-16 WO PCT/US2011/036657 patent/WO2011143653A2/en active Application Filing
- 2011-05-16 AU AU2011252792A patent/AU2011252792C1/en active Active
- 2011-05-16 LT LTEP14162929.5T patent/LT2772265T/lt unknown
-
2012
- 2012-11-14 US US13/694,280 patent/US9249427B2/en active Active
-
2015
- 2015-10-01 US US14/872,756 patent/US9982241B2/en active Active
-
2016
- 2016-03-23 AU AU2016201853A patent/AU2016201853A1/en not_active Abandoned
-
2018
- 2018-02-13 HR HRP20180267TT patent/HRP20180267T1/hr unknown
- 2018-02-26 CY CY20181100226T patent/CY1119944T1/el unknown
- 2018-04-16 HR HRP20180601TT patent/HRP20180601T1/hr unknown
- 2018-04-17 CY CY20181100413T patent/CY1120464T1/el unknown
- 2018-04-27 US US15/965,246 patent/US11266732B2/en active Active
- 2018-05-09 AU AU2018203259A patent/AU2018203259A1/en not_active Abandoned
- 2018-12-10 HK HK18115806.2A patent/HK1256651A1/zh unknown
- 2018-12-18 HK HK18116180.6A patent/HK1257045A1/zh unknown
-
2019
- 2019-07-11 AU AU2019204982A patent/AU2019204982B2/en active Active
-
2020
- 2020-04-30 HR HRP20200698TT patent/HRP20200698T1/hr unknown
- 2020-05-05 CY CY20201100410T patent/CY1124015T1/el unknown
- 2020-09-01 CY CY20201100816T patent/CY1123362T1/el unknown
- 2020-09-03 HR HRP20201406TT patent/HRP20201406T1/hr unknown
-
2022
- 2022-02-22 AU AU2022201186A patent/AU2022201186A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180267T1 (hr) | Rekombinantni hcmv i rhcmv vektori i njihovo korištenje | |
HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
Wang | Nonhuman primate models for Epstein-Barr virus infection | |
Münz | Humanized mouse models for Epstein Barr virus infection | |
Karstentischer et al. | Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli | |
CO2018006706A2 (es) | Virus mutados, método de preparación y uso de los mismos | |
MY197376A (en) | A rationally oeveloped afrigan swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 tsolate | |
PE20150334A1 (es) | Virus del herpes aviar recombinantes multivalentes y vacunas para inmunizar especies aviares | |
Muraro et al. | Fighting viral infections and virus-driven tumors with cytotoxic CD4+ T cells | |
Laursen et al. | Characterizaton of gamma delta T cells in Marek’s disease virus (Gallid herpesvirus 2) infection of chickens | |
MX2015007723A (es) | PARVOVIRUS PORCINO 5ª, METODOS DE USO Y VACUNA. | |
NZ702146A (en) | Peptides derived from viral proteins for use as immunogens and dosage reactants | |
Hicks et al. | Current state of Marek's disease virus microRNA research | |
Vélez-Bohórquez et al. | The viruses in the human oncogenesis | |
Sullivan et al. | Non-coding regulatory RNAs of the DNA tumor viruses | |
Sall et al. | Role of Epstein-Barr Virus Zebra protein in induction of t (8; 14) translocation. | |
Sousa | Investigation of Lana: A Human Virus Tumor Gene | |
Silva | KSHV LANA WIN-like motif influence on in vivo persistent infection | |
Royer et al. | 218: Mechanisms of lytic HSV-1 clearance during primary infection of the trigeminal ganglia | |
Faber | Recombinant rabies virus vaccines | |
González-Mariscal et al. | Development of in vitro systems to study IFN signalling in gilthead seabream (Sparus aurata) | |
LI et al. | Seven major genomic deletions of vaccinia virus Tiantan (VTT) is sufficient to decreased Pathogenicity | |
Alharbi | New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector | |
Sha-sha et al. | The Research Progress on Simian Cytomegalovirus | |
Mai et al. | Functions of V-val subtype of Epstein-Barr nuclear antigen 1 |